293 related articles for article (PubMed ID: 8732755)
1. Structural investigation of the alpha-1-antichymotrypsin: prostate-specific antigen complex by comparative model building.
Villoutreix BO; Lilja H; Pettersson K; Lövgren T; Teleman O
Protein Sci; 1996 May; 5(5):836-51. PubMed ID: 8732755
[TBL] [Abstract][Full Text] [Related]
2. A structural model for the prostate disease marker, human prostate-specific antigen.
Villoutreix BO; Getzoff ED; Griffin JH
Protein Sci; 1994 Nov; 3(11):2033-44. PubMed ID: 7535613
[TBL] [Abstract][Full Text] [Related]
3. Structural comparison of prostate-specific antigen and human glandular kallikrein using molecular modeling.
Bridon DP; Dowell BL
Urology; 1995 May; 45(5):801-6. PubMed ID: 7538242
[TBL] [Abstract][Full Text] [Related]
4. Kininogenase activity of prostate-derived human glandular kallikrein (hK2) purified from seminal fluid.
Charlesworth MC; Young CY; Miller VM; Tindall DJ
J Androl; 1999; 20(2):220-9. PubMed ID: 10232657
[TBL] [Abstract][Full Text] [Related]
5. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
6. Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
Björk T; Schalken J; Wittjes W; Ljungberg B; Lilja H
Prostate; 2001 Apr; 47(1):14-20. PubMed ID: 11304725
[TBL] [Abstract][Full Text] [Related]
7. Complex formation between human prostate-specific antigen and protease inhibitors in mouse plasma.
Hekim C; Riipi T; Zhu L; Laakkonen P; Stenman UH; Koistinen H
Prostate; 2010 Apr; 70(5):482-90. PubMed ID: 19937596
[TBL] [Abstract][Full Text] [Related]
8. Characterization and processing of prostate specific antigen (hK3) and human glandular kallikrein (hK2) secreted by LNCaP cells.
Väisänen V; Lövgren J; Hellman J; Piironen T; Lilja H; Pettersson K
Prostate Cancer Prostatic Dis; 1999 Mar; 2(2):91-97. PubMed ID: 12496845
[TBL] [Abstract][Full Text] [Related]
9. Structural model of human PSA: a target for prostate cancer therapy.
Hassan MI; Kumar V; Singh TP; Yadav S
Chem Biol Drug Des; 2007 Sep; 70(3):261-7. PubMed ID: 17718721
[TBL] [Abstract][Full Text] [Related]
10. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2.
Kumar A; Mikolajczyk SD; Goel AS; Millar LS; Saedi MS
Cancer Res; 1997 Aug; 57(15):3111-4. PubMed ID: 9242434
[TBL] [Abstract][Full Text] [Related]
11. Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids.
Lövgren J; Valtonen-André C; Marsal K; Lilja H; Lundwall A
J Androl; 1999; 20(3):348-55. PubMed ID: 10386814
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel complex between human kallikrein 2 and protease inhibitor-6 in prostate cancer tissue.
Mikolajczyk SD; Millar LS; Marker KM; Rittenhouse HG; Wolfert RL; Marks LS; Charlesworth MC; Tindall DJ
Cancer Res; 1999 Aug; 59(16):3927-30. PubMed ID: 10463585
[TBL] [Abstract][Full Text] [Related]
13. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells.
Veveris-Lowe TL; Lawrence MG; Collard RL; Bui L; Herington AC; Nicol DL; Clements JA
Endocr Relat Cancer; 2005 Sep; 12(3):631-43. PubMed ID: 16172196
[TBL] [Abstract][Full Text] [Related]
14. Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing.
Denmeade SR; Lövgren J; Khan SR; Lilja H; Isaacs JT
Prostate; 2001 Jul; 48(2):122-6. PubMed ID: 11433422
[TBL] [Abstract][Full Text] [Related]
15. Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer.
Pannek J; Rittenhouse HG; Evans CL; Finlay JA; Bruzek DJ; Cox JL; Chan DW; Subong EN; Partin AW
Urology; 1997 Nov; 50(5):715-21. PubMed ID: 9372881
[TBL] [Abstract][Full Text] [Related]
16. Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumors.
Fisher TL; Nocera M; Willis RA; Turner MJ; Abdul Alim CS; Brown DM; Bourne PA; di Sant'Agnese PA; Messing EM; Lord EM; Frelinger JG
Prostate; 2002 May; 51(3):153-65. PubMed ID: 11967950
[TBL] [Abstract][Full Text] [Related]
17. Affinity and specificity of serine endopeptidase-protein inhibitor interactions. Empirical free energy calculations based on X-ray crystallographic structures.
Krystek S; Stouch T; Novotny J
J Mol Biol; 1993 Dec; 234(3):661-79. PubMed ID: 8254666
[TBL] [Abstract][Full Text] [Related]
18. Modeling of prostate specific antigen and human glandular kallikrein structures.
Vihinen M
Biochem Biophys Res Commun; 1994 Nov; 204(3):1251-6. PubMed ID: 7526861
[TBL] [Abstract][Full Text] [Related]
19. Physicochemical conditions affecting the formation/stability of serum complexes and the determination of prostate-specific antigen (PSA).
Kioukia-Fougia N; Christofidis I; Strantzalis N
Anticancer Res; 1999; 19(4B):3315-20. PubMed ID: 10652627
[TBL] [Abstract][Full Text] [Related]
20. Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors.
Mikolajczyk SD; Millar LS; Kumar A; Saedi MS
Prostate; 1998 Jan; 34(1):44-50. PubMed ID: 9428387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
